Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis

NCT02435992 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02435992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02435992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
June 17, 2015
Completion date
June 17, 2020
Enrollment
1,012 (actual)
Sites
372

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis